CureVac’s Final Chapter: Nasdaq Exit Confirmed Following BioNTech Acquisition

CureVac NL0015436031

The independent journey of CureVac as a publicly traded company has reached its conclusion. The Tübingen-based vaccine developer is now on the verge of a Nasdaq delisting, a direct outcome of its successful acquisition by rival BioNTech. For remaining shareholders, a final countdown has begun, marking the end of the firm’s autonomy and paving the way for the compulsory buyout of minority interests.

BioNTech has cleared a critical milestone in the takeover process. Following the expiration of an additional acceptance period, the Mainz-based company now commands approximately 86.75 percent of CureVac’s outstanding shares. This figure comfortably surpasses the 80 percent minimum threshold required to proceed with the transaction.